Accord Healthcare Ltd.
https://www.accord-healthcare.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Accord Healthcare Ltd.
One Foot In The Door? Trio Look To Reenter Annulled EU Generic Tecfidera Market
A topsy-turvy legal battle going back some years led to a raft of Tecfidera generics being pulled from the market in December last year. Now, three of the affected companies are a step closer to reentering the market, which is set to remain a Tecfidera monopoly until February 2025.
EMA Says Yes To 12 New Drugs Including Pfizer/AbbVie’s Antibiotic Combo
Emblaveo, for fighting infections caused by multidrug-resistant bacteria, is among the latest batch of medicines that the European Medicines Agency says should be approved for use in the EU.
‘The US Is Catching Up’ – Accord’s Kokino On Biosimilar Market Dynamics
In the second part of his interview with Generics Bulletin, Chrys Kokino – president of Accord US – talks about how the US biosimilars market is catching up with Europe, as well as discussing aspects such as PBMs, the Inflation Reduction Act and biosimilar interchangeability.
‘We Are Going To Be Deeply Engaged In The Biosimilar Arena’ – Accord BioPharma Sets Out US Strategy
Hot on the heels of Accord BioPharma recently announcing a US filing for a Stelara biosimilar – as well as a settlement that will let it enter the market in May 2025 – Chrys Kokino, president of Accord US, talks about how the product fits into the firm’s wider biosimilars strategy in the first part of a two-part interview with Generics Bulletin.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice